State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France
Abstract
:1. Introduction
2. Materials and Methods
2.1. Choice of the Population Studied
2.2. Creation of the Questionnaire for Health Professionals and Students
2.3. Validation
2.4. Distribution of the Survey Questionnaire
3. Results
3.1. Description of the Study Population
- -
- Forty responders were neither health professionals nor students.
- -
- Five responders were excluded because they did not answer this questionnaire seriously.
- -
- Twenty-five professionals not exercising a profession concerned by this study.
- -
- Ten students not completing a course concerned by this study.
- -
- One physiotherapy student who is the only one in his specialty to have responded to the survey questionnaire.
- -
- One pharmacy technician student who is the only one in his specialty to have responded to the survey questionnaire.
3.2. Health Students
3.3. Health Professionals
4. Discussion
4.1. Reliability of Responses to the Survey Questionnaire
4.2. Age Group Distribution in the Responded Population
4.3. Level of General Knowledge
4.4. Level of Knowledge on HIV
4.5. Level of Knowledge on Hepatitis A
4.6. Level of Knowledge on Hepatitis B
4.7. Level of Knowledge on Hepatitis C
4.8. Level of Knowledge on Syphilis
4.9. Level of Knowledge on Papillomavirus
4.10. Level of Knowledge on Chlamydia Infection
4.11. Level of Knowledge on Gonococcal Infection
4.12. Level of Knowledge on Herpes Infections
5. Strengths and Limitations
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Available online: https://www.who.int/fr/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) (accessed on 30 December 2023).
- Ndeikoundam Ngangro, N.; Viriot, D.; Fournet, N.; Pioche, C.; De Barbeyrac, B.; Goubard, A.; Dupin, N.; Berçot, B.; Fouéré, S.; Alcaraz, I.; et al. Bacterial sexually transmitted infections in France: Recent trends and patients’ characteristics in 2016. Eurosurveillance 2019, 24, 1800038. [Google Scholar] [CrossRef]
- Available online: https://www.ecdc.europa.eu/en/sexually-transmitted-infections (accessed on 19 February 2024).
- Available online: https://www.cdc.gov/std/life-stages-populations/stdfact-teens.htm (accessed on 30 December 2023).
- Available online: https://www.nichd.nih.gov/health/topics/stds/conditioninfo/causes (accessed on 30 December 2023).
- Kumi Smith, M.; Jewell, B.L.; Hallett, T.B.; Cohen, M.S. Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. Adv. Exp. Med. Biol. 2018, 1075, 125–162. [Google Scholar] [CrossRef] [PubMed]
- Migueres, M.; Lhomme, S.; Izopet, J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses 2021, 13, 1900. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://www.cdc.gov/std/statistics/2021/overview.htm (accessed on 30 December 2023).
- Available online: https://www.cdc.gov/std/treatment-guidelines/references.htm (accessed on 30 December 2023).
- Available online: https://link.springer.com/chapter/10.1007/978-3-030-02200-6_1 (accessed on 30 December 2023).
- Available online: https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-727 (accessed on 30 December 2023).
- Available online: https://www.cdc.gov/std/statistics/2021/tables/1.htm (accessed on 30 December 2023).
- Available online: https://apps.who.int/iris/bitstream/handle/10665/246296/WHO-RHR-16.09-eng.pdf (accessed on 30 December 2023).
- Available online: https://www.cdc.gov/std/statistics/2021/default.htm (accessed on 30 December 2023).
- Available online: https://www.cdc.gov/std/statistics/default.htm? (accessed on 30 December 2023).
- Stoltey, J.E.; Cohen, S.E. Syphilis transmission: A review of the current evidence. Sex. Health 2015, 12, 103–109. [Google Scholar] [CrossRef] [PubMed]
- Winer, R.L.; Hughes, J.P.; Feng, Q.; O’Reilly, S.; Kiviat, N.B.; Holmes, K.K.; Koutsky, L.A. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 2006, 354, 2645–2654. [Google Scholar] [CrossRef] [PubMed]
- Peeling, R.W.; Mabey, D.; Chen, X.S.; Garcia, P.J. Syphilis. Lancet 2023, 402, 336–346. [Google Scholar] [CrossRef] [PubMed]
- Tortolero-Luna, G. Epidemiology of genital human papillomavirus. Hematol. Oncol. Clin. N. Am. 1999, 13, 245–257. [Google Scholar] [CrossRef] [PubMed]
- Browne, S.; Feemster, K.A. Human papillomavirus: Optimizing opportunities for prevention. Curr. Opin. Pediatr. 2022, 34, 132–139. [Google Scholar] [CrossRef]
- Vashisht, S.; Mishra, H.; Mishra, P.K.; Ekielski, A.; Talegaonkar, S. Structure, Genome, Infection Cycle and Clinical Manifestations Associated with Human Papillomavirus. Curr. Pharm. Biotechnol. 2019, 20, 1260–1280. [Google Scholar] [CrossRef] [PubMed]
- Ahmadi, M.H.; Mirsalehian, A.; Bahador, A. Association of Chlamydia trachomatis with infertility and clinical manifestations: A systematic review and meta-analysis of case-control studies. Infect. Dis. 2016, 48, 517–523. [Google Scholar] [CrossRef]
- Elwell, C.; Mirrashidi, K.; Engel, J. Chlamydia cell biology and pathogenesis. Nat. Rev. Microbiol. 2016, 14, 385–400. [Google Scholar] [CrossRef] [PubMed]
- Bébéar, C.; de Barbeyrac, B. Genital Chlamydia trachomatis infections. Clin. Microbiol. Infect. 2009, 15, 4–10. [Google Scholar] [CrossRef] [PubMed]
- Moreno, I.; Cicinelli, E.; Garcia-Grau, I.; Gonzalez-Monfort, M.; Bau, D.; Vilella, F.; De Ziegler, D.; Resta, L.; Valbuena, D.; Simon, C. The diagnosis of chronic endometritis in infertile asymptomatic women: A comparative study of histology, microbial cultures, hysteroscopy, and molecular microbiology. Am. J. Obs. Gynecol. 2018, 218, 602.e1–602.e16. [Google Scholar] [CrossRef] [PubMed]
- Garner, A.L.; Schembri, G.; Cullen, T.; Lee, V. Should we screen heterosexuals for extra-genital chlamydial and gonococcal infections? Int. J. STD AIDS 2015, 26, 462–466. [Google Scholar] [CrossRef]
- Hook, E.W., 3rd; Holmes, K.K. Gonococcal infections. Ann. Intern. Med. 1985, 102, 229–243. [Google Scholar] [CrossRef] [PubMed]
- Corey, L.; Adams, H.G.; Brown, Z.A.; Holmes, K.K. Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Ann. Intern. Med. 1983, 98, 958–972. [Google Scholar] [CrossRef] [PubMed]
- Omarova, S.; Cannon, A.; Weiss, W.; Bruccoleri, A.; Puccio, J. Genital Herpes Simplex Virus-An Updated Review. Adv. Pediatr. 2022, 69, 149–162. [Google Scholar] [CrossRef] [PubMed]
- Jaishankar, D.; Shukla, D. Genital Herpes: Insights into Sexually Transmitted Infectious Disease. Microb. Cell 2016, 3, 438–450. [Google Scholar] [CrossRef]
- OMS|Projet de Stratégie Mondiale du Secteur de la Santé sur le VIH/Sida, 2016–2021. Available online: https://www.who.int/hiv/proposed-hiv-strategy2016-2021/fr/ (accessed on 29 October 2019).
- Antela, A.; Aguiar, C.; Compston, J.; Hendry, B.M.; Boffito, M.; Mallon, P.; Pourcher-Martinez, V.; Di Perri, G. The role of tenofovir alafenamide in future HIV management. HIV Med. 2016, 17 (Suppl. S2), 4–16. [Google Scholar] [CrossRef]
- Fung, H.B.; Stone, E.A.; Piacenti, F.J. Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin. Ther. 2002, 24, 1515–1548. [Google Scholar] [CrossRef]
- Quercia, R.; Perno, C.F.; Koteff, J.; Moore, K.; McCoig, C.; St Clair, M.; Kuritzkes, D. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. J. Acquir. Immune Defic. Syndr. 2018, 78, 125–135. [Google Scholar] [CrossRef]
- Perry, C.M.; Faulds, D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997, 53, 657–680. [Google Scholar] [CrossRef]
- Wang, L.H.; Begley, J.; St Claire, R.L., 3rd; Harris, J.; Wakeford, C.; Rousseau, F.S. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses 2004, 20, 1173–1182. [Google Scholar] [CrossRef] [PubMed]
- Modrzejewski, K.A.; Herman, R.A. Emtricitabine: A once-daily nucleoside reverse transcriptase inhibitor. Ann. Pharmacother. 2004, 38, 1006–1014. [Google Scholar] [CrossRef] [PubMed]
- Frampton, J.E.; Perry, C.M. Emtricitabine: A review of its use in the management of HIV infection. Drugs 2005, 65, 1427–1448. [Google Scholar] [CrossRef]
- Available online: https://www.vidal.fr/sante/voyage/avant-voyage/vaccins-voyage/hepatite-a.html (accessed on 30 December 2023).
- Zoulim, F. Entecavir: A new treatment option for chronic hepatitis B. J. Clin. Virol. 2006, 36, 8–12. [Google Scholar] [CrossRef]
- Osborn, M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect. Drug Resist. 2011, 4, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Tenofovir Alafenamide: A Review in Chronic Hepatitis B. Drugs 2017, 77, 1017–1028. [CrossRef]
- Jaeckel, E.; Manns, M.P. Experience with lamivudine against hepatitis B virus. Intervirology 1997, 40, 322–336. [Google Scholar] [CrossRef]
- Schiff, E.R. Lamivudine for hepatitis B in clinical practice. J. Med. Virol. 2000, 61, 386–391. [Google Scholar] [CrossRef]
- Available online: https://www.vidal.fr/medicaments/utilisation/vaccins/vaccin-hepatite-b.html (accessed on 30 December 2023).
- Kwo, P.Y. Boceprevir: A novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Ther. Adv. Gastroenterol. 2012, 5, 179–188. [Google Scholar] [CrossRef]
- Chang, M.H.; Gordon, L.A.; Fung, H.B. Boceprevir: A protease inhibitor for the treatment of hepatitis C. Clin. Ther. 2012, 34, 2021–2038. [Google Scholar] [CrossRef]
- Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G.R.; Horban, A.; et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 364, 2417–2428. [Google Scholar] [CrossRef]
- Jesudian, A.B.; Jacobson, I.M. Optimal treatment with telaprevir for chronic HCV infection. Liver Int. 2013, 33 (Suppl. S1), 3–13. [Google Scholar] [CrossRef]
- Galvao, T.F.; Silva, M.T.; Serruya, S.J.; Newman, L.M.; Klausner, J.D.; Pereira, M.G.; Fescina, R. Safety of benzathine penicillin for preventing congenital syphilis: A systematic review. PLoS ONE 2013, 8, e56463. [Google Scholar] [CrossRef]
- Chen, X.; Li, G.; Gan, Y.; Chu, T.; Liu, D. Availability of benzathine penicillin G for syphilis treatment in Shandong Province, Eastern China. BMC Health Serv. Res. 2019, 19, 188. [Google Scholar] [CrossRef] [PubMed]
- Dai, T.; Qu, R.; Liu, J.; Zhou, P.; Wang, Q. Efficacy of Doxycycline in the Treatment of Syphilis. Antimicrob. Agents Chemother. 2016, 61, e01092-16. [Google Scholar] [CrossRef]
- Psomas, K.C.; Brun, M.; Causse, A.; Atoui, N.; Reynes, J.; Le Moing, V. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med. Mal. Infect. 2012, 42, 15–19. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://www.vidal.fr/medicaments/utilisation/vaccins/vaccin-papillomavirus.html (accessed on 30 December 2023).
- Foulds, G.; Shepard, R.M.; Johnson, R.B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 1990, 25 (Suppl. SA), 73–82. [Google Scholar] [CrossRef]
- Geisler, W.M.; Uniyal, A.; Lee, J.Y.; Lensing, S.Y.; Johnson, S.; Perry, R.C.; Kadrnka, C.M.; Kerndt, P.R. Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection. N. Engl. J. Med. 2015, 373, 2512–2521. [Google Scholar] [CrossRef]
- Ring, J. Highlights from the Journal of the European Academy of Dermatology and Venereology in 2022. J. Eur. Acad. Dermatol. Venereol. 2023, 37, 9–11. [Google Scholar] [CrossRef] [PubMed]
- Pronovost, A.D.; Lucia, H.L.; Dann, P.R.; Hsiung, G.D. Effect of acyclovir on genital herpes in guinea pigs. J. Infect. Dis. 1982, 145, 904–908. [Google Scholar] [CrossRef] [PubMed]
- Ormrod, D.; Goa, K. Valaciclovir: A review of its use in the management of herpes zoster. Drugs 2000, 59, 1317–1340. [Google Scholar] [CrossRef] [PubMed]
- Hull, C.; Spruance, S.; Tyring, S.; Hamed, K. Single-dose famciclovir for the treatment of herpes labialis. Curr. Med. Res. Opin. 2006, 22, 1699–1702. [Google Scholar] [CrossRef] [PubMed]
- Lowndes, C.M.; Fenton, K.A.; European Surveillance of STI’s Network. Surveillance systems for STIs in the European Union: Facing a changing epidemiology. Sex. Transm. Infect. 2004, 80, 264–271. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://doi.org/10.1016/j.lanepe.2023.100743 (accessed on 19 February 2024).
- Garcia, P.J.; Benzaken, A.S.; Galban, E.; ALAC-ITS members. STI management and control in Latin America: Where do we stand and where do we go from here? Sex. Transm. Infect. 2011, 87 (Suppl. S2), ii7–ii9. [Google Scholar] [CrossRef] [PubMed]
- Mahboob, N.; Iqbal, H.; Afrin, S.; Abedin, F.Z.; Ahmed, M. Assessment of Knowledge and Attitude about Sexually Transmitted Infections among Medical Students of Dhaka City, Bangladesh. Saudi J. Pathol. Microbiol. 2022, 7, 313–320. [Google Scholar] [CrossRef]
- Phrasisombath, K.; Thomsen, S.; Hagberg, J.; Sychareun, V.; Faxelid, E. Knowledge about sexually transmitted infections (STIs) and attitudes toward female sex workers with STI symptoms among health care providers in Laos. Asia Pac. J. Public Health 2012, 24, 940–952. [Google Scholar] [CrossRef]
- Folasayo, A.T.; Oluwasegun, A.J.; Samsudin, S.; Saudi, S.N.; Osman, M.; Hamat, R.A. Assessing the Knowledge Level, Attitudes, Risky Behaviors and Preventive Practices on Sexually Transmitted Diseases among University Students as Future Healthcare Providers in the Central Zone of Malaysia: A Cross-Sectional Study. Int. J. Environ. Res. Public Health 2017, 14, 159. [Google Scholar] [CrossRef]
- Mashingaidze, R.; Moodie, Z.; Allen, M.; Bekker, L.G.; Grove, D.; Grunenberg, N.; Huang, Y.; Janes, H.E.; Lazarus, E.M.; Malahleha, M.; et al. Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa. PLOS Glob. Public Health 2023, 3, e0001782. [Google Scholar] [CrossRef]
- Werner, R.N.; Gaskins, M.; Nast, A.; Dressler, C. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection—A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE 2018, 13, e0208107. [Google Scholar] [CrossRef] [PubMed]
- Alexander, T.S. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clin. Vaccine Immunol. 2016, 23, 249–253. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control y Prevention. Quick Reference Guide. Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens. 2018. Available online: https://stacks.cdc.gov/view/cdc/50872 (accessed on 19 February 2024).
- Griffin, D.O. The diagnosis of symptomatic acute antiretroviral syndrome during the window period with antigen/antibody testing and HIV viral load. IDCases 2018, 12, 157–160. [Google Scholar] [CrossRef] [PubMed]
- Alshuwaykh, O.; Kwo, P.Y. Current and future strategies for the treatment of chronic hepatitis C. Clin. Mol. Hepatol. 2021, 27, 246–256. [Google Scholar] [CrossRef]
- Farci, P.; Alter, H.J.; Shimoda, A.; Govindarajan, S.; Cheung, L.C.; Melpolder, J.C.; Sacher, R.A.; Shih, J.W.; Purcell, R.H. Hepatitis C virus-associated fulminant hepatic failure. N. Engl. J. Med. 1996, 335, 631–634. [Google Scholar] [CrossRef]
Pathogen | Sexual Transmission | Clinical Information and Symptoms | Epidemiological Data | References |
---|---|---|---|---|
HIV | Sexual contact with infected person’s blood, semen, vaginal fluids. | HIV is a virus that attacks the immune system and can lead to acquired immunodeficiency syndrome (AIDS). Symptoms of HIV can include fever, fatigue, rash, headache, sore throat, swollen lymph nodes, and mouth sores. There is no curative treatment for HIV, but antiretroviral therapy can help manage the virus and prevent progression to AIDS. | In 2020, WHO estimated 1.5 million new HIV infections globally. | [1,4,5,6] |
Hepatitis A | Sexual contact with infected person’s feces. | Hepatitis A is a viral infection that affects the liver. Symptoms of hepatitis A can include fever, fatigue, nausea, vomiting, abdominal pain, dark urine, and jaundice. Most people recover fully from hepatitis A with lifelong immunity. | In 2019, there were an estimated 1.5 million cases of hepatitis A worldwide. | [1,7,8,9] |
Hepatitis B | Sexual contact with infected person’s blood, semen, or vaginal fluids. | Hepatitis B is a viral infection that affects the liver. Symptoms of hepatitis B can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and jaundice. Chronic hepatitis B can lead to liver damage, cirrhosis, and liver cancer. A vaccine is available to prevent hepatitis B. | In 2019, there were an estimated 296 million people living with chronic hepatitis B globally. | [1,10,11,12] |
Hepatitis C | Sexual contact with infected person’s blood. | Hepatitis C is a viral infection that affects the liver. Symptoms of hepatitis C can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and jaundice. Chronic hepatitis C can lead to liver damage, cirrhosis, and liver cancer. New treatments are now available that can cure more than 95% of people with hepatitis C. | In 2019, there were an estimated 58 million people living with chronic hepatitis C globally. | [1,13,14,15] |
Syphilis | Sexual contact with infected person’s syphilis sore. | Syphilis is a bacterial infection that is primarily spread through sexual contact. Symptoms of syphilis can include sores, rashes, fever, fatigue, and swollen lymph nodes. If left untreated, syphilis can lead to serious health problems, including blindness, deafness, and dementia. Syphilis can be cured with antibiotics. | In 2020, WHO estimated 7.1 million new cases of syphilis globally. | [1,16,17,18] |
Papillomavirus | Sexual contact with infected person’s skin or mucous membranes. | Papillomavirus is a viral infection that is primarily spread through sexual contact. Most people with papillomavirus do not develop symptoms, but some types of the virus can cause genital warts or cancer. A vaccine is available to prevent certain types of papillomavirus. | In 2020, WHO estimated 570,000 new cases of cervical cancer worldwide. | [1,19,20,21] |
Chlamydia | Sexual contact with infected person’s semen or vaginal fluids. | Chlamydia is a bacterial infection that is primarily spread through sexual contact. Most people with chlamydia do not develop symptoms, but it can cause serious health problems if left untreated, including infertility. Chlamydia can be cured with antibiotics. | In 2020, WHO estimated 129 million new cases of chlamydia globally. | [1,22,23,24] |
Gonococcal infection | Sexual contact with infected person’s semen or vaginal fluids. | Gonococcal infection is a bacterial infection that is primarily spread through sexual contact. Symptoms of gonococcal infection can include discharge, pain, and bleeding. If left untreated, gonococcal infection can lead to serious health problems, including infertility. Gonococcal infection can be cured with antibiotics. | In 2020, WHO estimated 82 million new cases of gonorrhea globally. | [1,25,26,27] |
Herpes | Sexual contact with infected person’s skin or mucous membranes. | Herpes simplex is a viral infection that is primarily spread through sexual contact. Symptoms of herpes simplex can include blisters, sores, and itching. There is no cure for herpes simplex, but antiviral medications can help manage symptoms and reduce the risk of transmission. | In 2016, more than 500 million people aged 15–49 years were estimated to have a genital infection with herpes simplex virus (HSV or herpes). | [1,28,29,30] |
Pathogen | Treatment | Structure | Reference |
---|---|---|---|
HIV | 1/tenofovir 2/lamivudine 3/emtricitabine | 1/[32,33] 2/[34,35] 3/[36,37,38] | |
Hepatitis A | Vaccination | AVAXIM, HAVRIX, VAQTA, TWINRIX (hepatitis A and hepatitis B), TYAVAX (hepatitis A and typhoid) | [39] |
Hepatitis B | 1/entecavir 2/tenofovir 3/lamivudine 4/Vaccination | ENGERIX B, HBVAXPRO, TWINRIX (hepatitis A and hepatitis B), HEXYON (multi-pathogen), INFANRIXHEXA (multi-pathogen), VAXELIS (multi-pathogen) | 1/[40,41] 2/[42] 3/[43,44] 4/[45] |
Hepatitis C | 1/boceprevir 2/telaprevir | 1/[46,47] 2/[48,49] | |
Syphilis | 1/benzathine penicillin 2/doxycycline 3/ceftriaxone | 1/[50,51] 2/[52] 3/[53] | |
Papillomavirus | Vaccination | CERVARIX (2 viral strains); GARDASIL 9 (9 viral strains) | [54] |
Chlamydia | 1/azithromycin 2/doxycycline | 1/[55,56] 2/[56] | |
Gonococcal infection | 1/ceftriaxone 2/cefixime 3/spectinomycin | 3 | [57] |
Herpes | 1/aciclovir 2/valaciclovir 3/famciclovir | 1/[58] 2/[59] 3/[60] |
Questions | Students | Total | ||||
---|---|---|---|---|---|---|
Dentistry | Nursing | Medicine | Pharmacy | Midwifery | ||
Q1: Profession? | 19.5% (62) | 11.6% (37) | 22.3% (71) | 37.6% (118) | 8.2% (26) | 100% (314) |
Q2: Mandatory STI reporting? | 4.8% (3/62) | 10.8% (4/37) | 12.7% (9/71) | 5.9% (7/118) | 7.7% (2/26) | 7.9% (25/314) |
Q3: STI due to bacteria? | 37.1% (23/62) | 16.2% (6/37) | 77.5% (55/71) | 83.9% (99/118) | 46.2% (12/26) | 62.1% (195/314) |
Q4: HIV transmission | 69.2% (39/62) | 78.4% (29/37) | 77.5% (55/71) | 79.7% (94/118) | 76.9% (20/26) | 75.5% (237/314) |
Q5: HIV manifestations | 3.2% (2/62) | 2.7% (1/37) | 45.1% (32/71) | 8.5% (10/118) | 15.4% (4/26) | 15.6% (49/314) |
Q6: HIV diagnostics | 85.5% (53/62) | 70.3% (26/37) | 98.6% (70/71) | 89% (105/118) | 80.8% (21/26) | 87.6% (275/314) |
Q7: HIV therapy | 72.6% (45/62) | 35.1% (13/37) | 94.4% (67/71) | 79.7% (94/118) | 84.6% (22/26) | 76.8% (241/314) |
Q8: HIV prevention | 14.5% (9/62) | 5.4% (2/37) | 40.8% (29/71) | 28.8% (34/118) | 34.6% (9/26) | 26.4% (83/314) |
Q9: Hepatitis A transmission | 25.8% (16/62) | 24.3% (9/37) | 49.3% (35/71) | 27.1% (32/118) | 34.6% (9/26) | 32.2% (101/314) |
Q10: Hepatitis A manifestations | 1.6% (1/62) | 0% (0/37) | 45.1% (32/71) | 10.2% (12/118) | 11.5% (3/26) | 15.3% (48/314) |
Q11: Hepatitis A screening | 72.6% (45/62) | 75.7% (28/37) | 98.6% (70/71) | 92.4% (109/118) | 96.2% (25/26) | 88.2% (277/314) |
Q12: Hepatitis A evolution | 12.9% (8/62) | 0% (0/37) | 57.7% (41/71) | 24.6% (29/118) | 7.7% (2/26) | 25.5% (80/314) |
Q13: Hepatitis A vaccine | 40.3% (25/62) | 40.5% (15/37) | 76.1% (54/71) | 74.5% (88/118) | 53.8% (14/26) | 62.4% (196/314) |
Q14: Hepatitis B transmission | 33.9% (21/62) | 8.1% (3/37) | 12.7% (9/71) | 10.2% (12/118) | 15.4% (4/26) | 15.6% (49/314) |
Q15: Hepatitis B manifestations | 3.2% (2/62) | 0% (0/37) | 50.7% (36/71) | 13.6% (16/118) | 26.9% (7/26) | 19.4% (61/314) |
Q16: Hepatitis B screening | 91.9% (57/62) | 89.2% (33/37) | 97.2% (69/71) | 95.8% (113/118) | 100% (26/26) | 94.9% (298/314) |
Q17: Hepatitis B evolution | 8.1% (5/62) | 0% (0/37) | 11.3% (8/71) | 11% (13/118) | 11.5% (3/26) | 9.2% (29/314) |
Q18: Hepatitis B vaccine | 91.9% (57/62) | 94.6% (35/37) | 98.6% (70/71) | 97.5% (115/118) | 100% (26/26) | 96.2% (303/314) |
Q19: Hepatitis C transmission | 11.3% (7/62) | 5.4% (2/37) | 11.3% (8/71) | 11% (13/118) | 3.8% (1/26) | 9.9% (31/314) |
Q20: Hepatitis C manifestations | 3.2% (2/62) | 0% (0/37) | 64.8% (46/71) | 15.3% (18/118) | 26.9% (7/26) | 23.2% (73/314) |
Q21: Hepatitis C screening | 90.3% (56/62) | 83.8% (31/37) | 95.8% (68/71) | 93.2% (110/118) | 100% (26/26) | 92.7% (291/314) |
Q22: Hepatitis C evolution | 3.2% (2/62) | 0% (0/37) | 18.3% (13/71) | 5.9% (7/118) | 0% (0/26) | 7% (22/314) |
Q23: Hepatitis C vaccine | 79% (49/62) | 62.2% (23/37) | 88.7% (63/71) | 87.3% (103/118) | 84.6% (22/26) | 82.8% (260/314) |
Q24: Syphilis transmission | 27.4% (17/62) | 8.1% (3/37) | 69% (49/71) | 43.2% (51/118) | 46.2% (12/26) | 42% (132/314) |
Q25: Syphilis manifestations | 1.6% (1/62) | 0% (0/37) | 16.9% (12/71) | 0.8% (1/118) | 7.7% (2/26) | 5.1% (16/314) |
Q26: Syphilis screening | 62.9% (39/62) | 45.9% (17/37) | 97.2% (69/71) | 72% (85/118) | 88.5% (23/26) | 74.2% (233/314) |
Q27: Syphilis evolution | 3.2% (2/62) | 2.7% (1/37) | 18.3% (13/71) | 6.8% (8/118) | 11.5% (3/26) | 8.6% (27/314) |
Q28: Syphilis vaccine | 93.5% (58/62) | 89.2% (33/37) | 97.2% (69/71) | 97.5% (115/118) | 100% (26/26) | 95.9% (301/314) |
Q29: HPV transmission | 22.6% (14/62) | 5.4% (2/37) | 64.8% (46/71) | 37.3% (44/118) | 46.2% (12/26) | 37.6% (118/314) |
Q30: HPV manifestations | 14.5% (9/62) | 0% (0/37) | 49.3% (35/71) | 18.6% (22/118) | 23.1% (6/26) | 22.9% (72/314) |
Q31: HPV screening | 72.6% (45/62) | 78.4% (22/37) | 91.5% (65/71) | 78% (92/118) | 92.3% (24/26) | 81.2% (255/314) |
Q32: HPV evolution | 19.4% (12/62) | 8.1% (3/37) | 73.2% (52/71) | 23.7% (28/118) | 23.1% (6/26) | 32.2% (101/314) |
Q33: HPV vaccine | 90.3% (56/62) | 89.2% (33/37) | 94.4% (67/71) | 98.3% (116/118) | 100% (26/26) | 94.9% (298/314) |
Q34: Chlamydia transmission | 30.6% (19/62) | 13.5% (5/37) | 42.3% (30/71) | 36.4% (43/118) | 50% (13/26) | 35% (110/314) |
Q35: Chlamydia manifestations | 3.2% (2/62) | 5.4% (2/37) | 25.4% (18/71) | 7.6% (9/118) | 11.5% (3/26) | 10.8% (34/314) |
Q36: Chlamydia screening | 11.3% (7/62) | 0% (0/37) | 35.2% (25/71) | 15,3% (18/118) | 26.9% (7/26) | 16.9% (57/314) |
Q37: Chlamydia evolution | 16.1% (10/62) | 10.8% (4/37) | 76.1% (54/71) | 47.5% (56/118) | 61.5% (16/26) | 44.6% (140/314) |
Q38: Chlamydia vaccine | 98.4% (61/62) | 89.2% (33/37) | 100% (71/71) | 100% (118/118) | 100% (26/26) | 98.4% (309/314) |
Q39: Gonococcus transmission | 14.5% (9/62) | 5.4% (2/37) | 52.1% (37/71) | 30.5% (36/118) | 30.8% (8/26) | 29.3% (92/314) |
Q40: Gonococcus manifestations | 3.2% (2/62) | 0% (0/37) | 26.8% (19/71) | 5.1% (6/118) | 7.7% (2/26) | 9.2% (29/314) |
Q41: Gonococcus screening | 8.1% (5/62) | 5.4% (2/37) | 29.6% (21/71) | 12.7% (15/118) | 23.1% (6/26) | 15.6% (49/314) |
Q42: Gonococcus evolution | 8.1% (5/62) | 8.1% (3/37) | 59.2% (42/71) | 37.3% (44/118) | 38.5% (10/26) | 33.1% (104/314) |
Q43: Gonococcus vaccine | 90.3% (56/62) | 89.2% (33/37) | 100% (71/71) | 99.2% (117/118) | 84.6% (22/26) | 95.2% (299/314) |
Q44: Herpes transmission | 58.1% (36/62) | 75.7% (28/37) | 85.9% (61/71) | 67.8% (80/118) | 84.6% (22/26) | 72.3% (227/314) |
Q45: Herpes manifestations | 33.9% (21/62) | 27% (10/37) | 25.4% (18/71) | 21.2% (25/118) | 23.1% (6/26) | 25.5% (80/314) |
Q46: Herpes screening | 43.5% (27/62) | 64.9% (24/37) | 63.4% (45/71) | 42.4% (50/118) | 50% (13/26) | 50.6% (159/318) |
Q47: Herpes evolution | 27.4% (17/62) | 40.5% (15/37) | 49.3% (35/71) | 46.6% (55/118) | 61.5% (16/26) | 43.9% (138/314) |
Q48: Herpes vaccine | 95.2% (59/62) | 94.6% (35/37) | 94.4% (67/71) | 96.6% (114/118) | 96.2% (25/26) | 95.5% (300/314) |
Questions | Professionals | Total | ||||||
---|---|---|---|---|---|---|---|---|
Dentists | Nurses | Medical Doctors | Pharmacists | PH | PT | Midwives | ||
Q1: Profession? | 1.2% (10) | 5.9% (48) | 27.5% (224) | 29.4% (240) | 2.7% (22) | 5.2% (42) | 28.1% (229) | 100% (815) |
Q2: Mandatory STI reporting? | 0% (0/10) | 8.3% (4/48) | 12.9% (29/224) | 10.8% (26/240) | 4.5% (1/22) | 4.8% (2/42) | 11.8% (27/229) | 10.9% (89/815) |
Q3: STI due to bacteria? | 70% (7/10) | 27.1% (13/48) | 78.1% (175/224) | 70% (168/240) | 18.2% (4/22) | 52.4% (22/42) | 54.1% (124/229) | 62.9% (513/815) |
Q4: HIV transmission | 60% (6/10) | 77.1% (37/48) | 67.4% (151/224) | 63.8% (153/240) | 59.1% (13/22) | 57.1% (24/42) | 80.8% (185/229) | 69.8% (569/818) |
Q5: HIV manifestations | 10% (1/10) | 4.2% (2/48) | 42.4% (95/224) | 9.6% (23/240) | 0% (0/22) | 0% (0/42) | 9.2% (21/229) | 17.4%% (142/815) |
Q6: HIV diagnostics | 80% (8/10) | 68.8% (33/48) | 90.2% (202/224) | 85% (204/240) | 90.9% (20/22) | 61.9% (26/42) | 81.2% (186/229) | 83.3% (679/815) |
Q7: HIV therapy | 40% (4/10) | 60.4% (29/48) | 89.7% (201/224) | 79.6% (191/240) | 50% (11/22) | 52.4% (22/42) | 79.5% (182/229) | 78.5% (640/815) |
Q8: HIV prevention | 10% (1/10) | 12.5% (6/48) | 47.3% (106/224) | 37.5% (90/240) | 0% (0/22) | 19% (8/42) | 25.8% (59/229) | 33,1% (270/815) |
Q9: Hepatitis A transmission | 20% (2/10) | 14.6% (7/48) | 33.5% (75/224) | 32.1% (77/240) | 13.6% (3/22) | 14.3% (6/42) | 17.9% (41/229) | 25.9% (211/815) |
Q10: Hepatitis A manifestations | 10% (1/10) | 0% (0/48) | 39.7% (89/224) | 5.4% (13/240) | 4.5% (1/22) | 2.4% (1/42) | 7.4% (17/229) | 15% (122/815) |
Q11: Hepatitis A screening | 90% (9/10) | 95.8% (46/48) | 99.1% (222/224) | 97.5% (234/240) | 0% (0/22) | 88.1% (37/42) | 91.7% (210/229) | 93% (758/815) |
Q12: Hepatitis A evolution | 30% (3/10) | 2.1% (1/48) | 52.7% (118/224) | 17.9% (43/240) | 0% (0/22) | 7.1% (3/42) | 10.9% (25/229) | 23.4% (191/815) |
Q13: Hepatitis A vaccine | 70% (7/10) | 62.5% (30/48) | 86.6% (194/224) | 90.8% (218/240) | 77.3% (17/22) | 71.4% (30/42) | 64.2% (147/229) | 78.9% (643/815) |
Q14: Hepatitis B transmission | 30% (3/10) | 8.3% (4/48) | 21% (47/224) | 14.6% (35/240) | 4.5% (1/22) | 16.7% (7/42) | 10.5% (24/229) | 14.8% (121/815) |
Q15: Hepatitis B manifestations | 0% (0/10) | 2.1% (1/48) | 47.3% (106/224) | 7.5% (18/240) | 9.1% (2/22) | 0% (0/42) | 12.7% (29/229) | 19.1% (156/815) |
Q16: Hepatitis B screening | 90% (9/10) | 95.8% (46/48) | 99.1% (222/224) | 97.5% (234/240) | 90.9% (20/22) | 88.1% (37/42) | 91.7% (210/229) | 95.5% (778/815) |
Q17: Hepatitis B evolution | 0% (0/10) | 0% (0/48) | 17% (38/224) | 2.1% (5/240) | 0% (0/22) | 4.8% (2/42) | 7.4% (17/229) | 7.6% (62/815) |
Q18: Hepatitis B vaccine | 100% (10/10) | 97.9% (47/48) | 99.6% (223/224) | 97.9% (235/240) | 81.8% (18/22) | 92.9% (39/42) | 99.6% (228/229) | 98.2% (800/815) |
Q19: Hepatitis C transmission | 20% (2/10) | 6.3% (3/48) | 16.1% (38/224) | 12.5% (30/240) | 9.1% (2/22) | 2.4% (1/42) | 13.5% (31/229) | 12.9% (105/815) |
Q20: Hepatitis C manifestations | 10% (1/10) | 8.3% (4/48) | 56.7% (127/224) | 11.7% (28/240) | 9.1% (2/22) | 2.4% (1/42) | 17.5% (40/229) | 24.9% (203/815) |
Q21: Hepatitis C screening | 100% (10/10) | 93.8% (45/48) | 98.7% (221/224) | 96.3% (231/240) | 95.5% (21/22) | 61.9% (26/42) | 98.7% (226/229) | 97.7% (796/815) |
Q22: Hepatitis C evolution | 0% (0/10) | 0% (0/48) | 14.3% (32/224) | 4.6% (11/240) | 0% (0/22) | 0% (0/42) | 3.9% (9/229) | 6.4% (52/815) |
Q23: Hepatitis C vaccine | 70% (7/10) | 81.3% (39/48) | 96.9% (217/224) | 90.4% (217/240) | 45.5% (10/22) | 81% (34/42) | 91.7% (210/229) | 90.1% (734/815) |
Q24: Syphilis transmission | 30% (3/10) | 16.7% (8/48) | 54.5% (122/224) | 36.3% (87/240) | 40.9% (9/22) | 28.6% (12/42) | 31.4% (72/229) | 38.4% (313/815) |
Q25: Syphilis manifestations | 0% (0/10) | 0% (0/48) | 9.8% (22/224) | 1.7% (4/240) | 4.5% (1/22) | 0% (0/42) | 2.2% (5/229) | 3.9% (32/815) |
Q26: Syphilis screening | 50% (5/10) | 79.2% (38/48) | 96.9% (217/224) | 78.8% (189/240) | 59.1% (13/22) | 76.2% (32/42) | 96.9% (222/229) | 87.9% (716/815) |
Q27: Syphilis evolution | 0% (0/10) | 4.2% (2/48) | 12.1% (27/224) | 5.4% (13/240) | 0% (0/22) | 4.8% (2/42) | 4.8% (11/229) | 6.7% (55/815) |
Q28: Syphilis vaccine | 100% (10/10) | 95.8% (46/48) | 99.1% (222/224) | 99.6% (239 /240) | 95.5% (21/22) | 100% (42/42) | 99.1% (227/229) | 99% (807/815) |
Q29: HPV transmission | 10% (1/10) | 16.7% (8/48) | 61.2% (137/224) | 33.3% (80/240) | 9.1% (2/22) | 7.1% (3/42) | 50.7% (116/229) | 42.6% (347/815) |
Q30: HPV manifestations | 20% (2/10) | 8.3% (4/48) | 51.3% (115/224) | 22.5% (55/240) | 0% (0/22) | 9.5% (4/42) | 44.5% (102/229) | 34.5% (281/815) |
Q31: HPV screening | 90% (9/10) | 70.8% (34/48) | 82.1% (184/224) | 81.7% (196/240) | 72.7% (16/22) | 73.8% (31/42) | 86% (197/229) | 81.8% (667/815) |
Q32: HPV evolution | 10% (1/10) | 2.1% (1/48) | 53.6% (120/224) | 25% (60/240) | 0% (0/22) | 9.5% (4/42) | 37.6% (86/229) | 33.4% (272/815) |
Q33: HPV vaccine | 100% (10/10) | 91.7% (44/48) | 98.2% (220/224) | 95% (228/240) | 86.4% (19/22) | 92.9% (39/42) | 100% (229/229) | 96.8% (789/815) |
Q34: Chlamydia transmission | 50% (5/10) | 27.1% (13/48) | 35.7% (80/224) | 26.3% (63/240) | 31.8% (7/22) | 21.4% (9/42) | 28.8% (66/229) | 29.8% (243/815) |
Q35: Chlamydia manifestations | 0% (0/10) | 2.1% (1/48) | 29.9% (67/224) | 6.3% (15/240) | 0% (0/22) | 2.4% (1/42) | 8.7% (20/229) | 12.8% (104/815) |
Q36: Chlamydia screening | 10% (1/10) | 4.2% (2/48) | 24.1% (54/224) | 10% (24/240) | 9.1% (2/22) | 7.1% (3/42) | 20.5% (47/229) | 16.3% (133/815) |
Q37: Chlamydia evolution | 30% (3/10) | 14.6% (7/48) | 68.8% (154/224) | 33.3% (80/240) | 18.2% (4/22) | 16.7% (7/42) | 55.9% (128/229) | 47% (383/815) |
Q38: Chlamydia vaccine | 100% (10/10) | 100% (48/48) | 100% (224/224) | 99.6% (239/240) | 100% (22/22) | 97.6% (41/42) | 100% (229/229) | 99.8% (813/815) |
Q39: Gonococcus transmission | 20% (2/10) | 10.4% (5/48) | 45.5% (102/224) | 27.9% (67/240) | 13.6% (3/22) | 19% (8/42) | 32.8% (75/229) | 32.1% (262/815) |
Q40: Gonococcus manifestations | 0% (0/10) | 2.1% (1/48) | 17.4% (39/224) | 4.2% (10/240) | 0% (0/22) | 4.8% (2/42) | 7.4% (17/229) | 8.5% (69/815) |
Q41: Gonococcus screening | 10% (1/10) | 2.1% (1/48) | 28.6% (64/224) | 12.9% (31/240) | 13.6% (3/22) | 2.4% (1/42) | 17.9% (41/229) | 17.4% (142/815) |
Q42: Gonococcus evolution | 30% (3/10) | 6.3% (3/48) | 46.9% (105/224) | 19.4% (47/240) | 4.5% (1/22) | 16.7% (7/42) | 37.6% (86/229) | 30.9% (252/815) |
Q43: Gonococcus vaccine | 100% (10/10) | 100% (48/48) | 99.6% (223/224) | 99.2% (238/240) | 100% (22/22) | 95.2% (40/42) | 100% (229/229) | 99.4% (810/815) |
Q44: Herpes transmission | 70% (7/10) | 60.4% (29/48) | 77.2% (173/224) | 63.3% (152/240) | 50% (11/22) | 73.8% (31/42) | 73.8% (169/229) | 70.2% (572/815) |
Q45: Herpes manifestations | 50% (5/10) | 18.8% (9/48) | 20.5% (46/224) | 21.3% (51/240) | 18.2% (4/22) | 23.8% (10/42) | 24.9% (57/229) | 22.3% (182/815) |
Q46: Herpes screening | 50% (5/10) | 41.7% (20/48) | 42.4% (95/224) | 51.7% (124/240) | 18.2% (4/22) | 61.9% (26/42) | 43.2% (99/229) | 45.8% (373/815) |
Q47: Herpes evolution | 50% (5/10) | 25% (12/48) | 46.4% (104/224) | 42.5% (102/240) | 27.3% (6/22) | 21.4% (9/42) | 42.8% (98/229) | 41.2% (336/815) |
Q48: Herpes vaccine | 100% (10/10) | 100% (48/48) | 95.1% (213/224) | 96.7% (232/240) | 100% (22/22) | 95.2% (40/42) | 97.8% (224/229) | 96.8% (789/815) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chlebus, M.; Boyer, L.; Doerper, S.; Hergot, T.; Varbanov, M. State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France. Venereology 2024, 3, 63-88. https://doi.org/10.3390/venereology3020006
Chlebus M, Boyer L, Doerper S, Hergot T, Varbanov M. State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France. Venereology. 2024; 3(2):63-88. https://doi.org/10.3390/venereology3020006
Chicago/Turabian StyleChlebus, Marine, Laurence Boyer, Sébastien Doerper, Tristan Hergot, and Mihayl Varbanov. 2024. "State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France" Venereology 3, no. 2: 63-88. https://doi.org/10.3390/venereology3020006